Kelly A. Copeland
Keine laufenden Positionen mehr
Profil
Kelly A.
Copeland worked as Vice President-Product Strategy at Ceptaris Therapeutics, Inc. from 2011 to 2012.
She also worked as VP-Business Development & Product Strategy at Ception Therapeutics, Inc., Vice President-Product Strategy at Aclaris Therapeutics, Inc., and Head-Commercial Strategy at GSK Plc.
Prior to her business career, she worked as a Principal at Henry Ford Health System.
Copeland received both undergraduate and graduate degrees from the University of Michigan.
Ehemalige bekannte Positionen von Kelly A. Copeland
| Unternehmen | Position | Ende |
|---|---|---|
| ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Ceptaris Therapeutics, Inc.
 Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Corporate Officer/Principal | - |
| GSK PLC | Corporate Officer/Principal | - |
Henry Ford Health System
 Henry Ford Health System Hospital/Nursing ManagementHealth Services Henry Ford Health System, Inc. engages in the provision of health care services. It offers services in the areas of addiction treatment, allergy and immunology, anesthesiology, autism and developmental disabilities, bariatric surgery center, behavioral health, cancer, center for integrative medicine, colon and rectal surgery, dermatology, diabetes, emergency, family medicine, gastroenterology, general surgery, genetics, heart and vascular, brain tumor, hospital medicine, infectious diseases, internal medicine and endocrinology, and bone mineral disorders. The company was founded by Henry Ford in 1915 and is headquartered in Detroit, MI. | Corporate Officer/Principal | - |
Ception Therapeutics, Inc.
 Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | Corporate Officer/Principal | - |
Ausbildung von Kelly A. Copeland
| University of Michigan | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GSK PLC | Health Technology |
| ACLARIS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | Health Technology |
Henry Ford Health System
Henry Ford Health System Hospital/Nursing ManagementHealth Services Henry Ford Health System, Inc. engages in the provision of health care services. It offers services in the areas of addiction treatment, allergy and immunology, anesthesiology, autism and developmental disabilities, bariatric surgery center, behavioral health, cancer, center for integrative medicine, colon and rectal surgery, dermatology, diabetes, emergency, family medicine, gastroenterology, general surgery, genetics, heart and vascular, brain tumor, hospital medicine, infectious diseases, internal medicine and endocrinology, and bone mineral disorders. The company was founded by Henry Ford in 1915 and is headquartered in Detroit, MI. | Health Services |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
